(Delayed Data from NSDQ)
$468.00 USD
468.00
1,090,352
-0.57 (-0.12%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $466.00 -2.00 (-0.43%) 7:58 PM ET
Zacks Rank:
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 23.68% |
| 2 | Buy | 17.55% |
| 3 | Hold | 9.21% |
| 4 | Sell | 4.93% |
| 5 | Strong Sell | 2.36% |
| S&P | 500 | 10.96% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
Style Scores:
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
DValue | FGrowth | FMomentum | FVGM
Industry Rank:
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Top 35% (86 out of 249)
Industry: Medical - Biomedical and Genetics
View All Zacks #1 Ranked Stocks
Vertex Pharmaceuticals (VRTX) Price Targets
| Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
|---|---|---|---|
| $506.11 | $600.00 | $325.00 | 8.01% |
Price Target
Based on short-term price targets offered by 27 analysts, the average price target for Vertex Pharmaceuticals comes to $506.11. The forecasts range from a low of $325.00 to a high of $600.00. The average price target represents an increase of 8.01% from the last closing price of $468.57.
Analyst Price Targets (27)
Last Close 468.57
Average 506.11 8.01% Upside Low 325.00 -30.64% Downside High 600.00 28.05% Upside
Broker Rating
Vertex Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.87 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 30 brokerage firms. The current ABR compares to an ABR of 1.87 a month ago based on 30 recommendations.
Of the 30 recommendations deriving the current ABR, 19 are Strong Buy, representing 63.33% of all recommendations. A month ago, Strong Buy represented 63.33%.
Broker Rating Breakdown
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 19 | 19 | 19 | 20 | 19 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 9 | 9 | 9 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 2 | 2 |
| ABR | 1.87 | 1.87 | 1.87 | 1.80 | 1.83 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
| Date | Brokerage Firm | Analyst | Previous | Current |
|---|---|---|---|---|
| 8/28/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
| 8/5/2024 | Not Identified | Not Identified | Strong Buy | Hold |
| 8/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
| 8/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
| 8/2/2024 | Not Identified | Not Identified | Hold | Hold |
| 8/2/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
| 8/1/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
| 7/31/2024 | Canaccord Genuity | Whitney Ijem | Strong Sell | Strong Sell |
| 7/26/2024 | Needham & Company | Joseph R Stringer | Hold | Hold |
| 7/23/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
| 7/19/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
| 7/16/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
| 6/27/2024 | Atlantic Equities | Steven K Chesney | Not Available | Strong Buy |
| 6/24/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
| 6/24/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
| 6/17/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
| 5/31/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
| 5/7/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
| 5/7/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
| 5/7/2024 | Not Identified | Not Identified | Hold | Hold |
| 5/7/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
| 5/7/2024 | Not Identified | Not Identified | Hold | Hold |
| 4/17/2024 | UBS | Colin N Bristow | Strong Buy | Strong Buy |
| 1/31/2024 | Robert W. Baird & Co. | Brian P Skorney | Hold | Strong Sell |
| 1/30/2024 | Maxim Group | Naz Rahman | Strong Buy | Hold |
| 12/1/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
| Current ABR Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for most of the leading investment web sties. The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc) made by the brokerage firms for a given stock. ABR vs Zacks Rank | 1.87 |
| ABR (Last week) | 1.87 |
| # of Recs in ABR | 30 |
| Average Target Price | $506.11 |
| LT Growth Rate | 12.50% |
| Industry | Medical - Biomedical and Genetics |
| Industry Rank by ABR | 86 of 253 |
| Current Quarter EPS Est: | 4.11 |
VRTX FAQs
Vertex Pharmaceuticals Incorporated (VRTX) currently has an average brokerage recommendation (ABR) of 1.87 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 30 brokerage firms.
The average price target for Vertex Pharmaceuticals Incorporated (VRTX) is $506.11. The current on short-term price targets is based on 12 reports.
The forecasts for Vertex Pharmaceuticals Incorporated (VRTX) range from a low of $325 to a high of $600. The average price target represents a increase of $8.14 from the last closing price of $468.00.
The current UPSIDE for Vertex Pharmaceuticals Incorporated (VRTX) is 8.14%
Based on short-term price targets offered by 27 analysts, the average price target for Vertex Pharmaceuticals comes to $506.11. The forecasts range from a low of $325.00 to a high of $600.00. The average price target represents an increase of 8.01% from the last closing price of $468.57.
